Physician profile
Christopher Dallo
NPI 1063071199
$3,549.54
in general payments reported to CMS, 2019-2025
13 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $247 · 2021: $1,016 · 2022: $785 · 2023: $847 · 2024: $355 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,219.45 | 2020-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $774.06 | 2021-2024 | |
| Amgen INC. | $455.78 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $390.22 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $191.88 | 2023-2024 | Sotyktu |
| Janssen Scientific Affairs, LLC | $134.59 | 2025 | Tremfya |
| Regeneron Pharmaceuticals, INC. | $123.76 | 2023 | Dupixent |
| Leo Pharma INC. | $87.49 | 2020-2023 | Adbry |
| Janssen Biotech, INC. | $75.85 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $36.47 | 2024-2025 | |
| Incyte Corporation | $24.43 | 2023 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $18.65 | 2025 | Dupixent |
| Pfizer INC. | $16.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.